![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
CK Goldman, J Kim, WL Wong, V King, T Brock and GY Gillespie
Brain Tumor Research Laboratories, Division of Neurosurgery, University of Alabama, Birmingham 35294-0006.
Hypervascularity, focal necrosis, persistent cerebral edema, and rapid cellular proliferation are key histopathologic features of glioblastoma multiforme (GBM), the most common and malignant of human brain tumors. By immunoperoxidase and immunofluorescence, we definitively have demonstrated the presence of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFr) in five out of five human glioma cell lines (U-251MG, U-105MG, D-65MG, D-54MG, and CH-235MG) and in eight human GBM tumor surgical specimens. In vitro experiments with glioma cell lines revealed a consistent and reliable relation between EGFr activation and VEGF production; namely, EGF (1-20 ng/ml) stimulation of glioma cells resulted in a 25-125% increase in secretion of bioactive VEGF. Conditioned media (CM) prepared from EGF-stimulated glioma cell lines produced significant increases in cytosolic free intracellular concentrations of Ca2+ ([Ca2+]i) in human umbilical vein endothelial cells (HUVECs). Neither EGF alone or CM from glioma cultures prepared in the absence of EGF induced [Ca2+]i increases in HUVECs. Preincubation of glioma CM with A4.6.1, a monoclonal antibody to VEGF, completely abolished VEGF-mediated [Ca2+]i transients in HUVECs. Likewise, induction by glioma-derived CM of von Willebrand factor release from HUVECs was completely blocked by A4.6.1 pretreatment. These observations provide a key link in understanding the basic cellular pathophysiology of GBM tumor angiogenesis, increased vascular permeability, and cellular proliferation. Specifically, EGF activation of EGFr expressed on glioma cells leads to enhanced secretion of VEGF by glioma cells. VEGF released by glioma cells in situ most likely accounts for pathognomonic histopathologic and clinical features of GBM tumors in patients, including striking tumor angiogenesis, increased cerebral edema and hypercoagulability manifesting as focal tumor necrosis, deep vein thrombosis, or pulmonary embolism.
This article has been cited by other articles:
|
|
 |
|
  M. Sakaguchi, H. Sonegawa, H. Murata, M. Kitazoe, J.-i. Futami, K. Kataoka, H. Yamada, and N.-h. Huh S100A11, an Dual Mediator for Growth Regulation of Human Keratinocytes Mol. Biol. Cell, January 1, 2008; 19(1): 78 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. V. Sharma and J. Settleman Oncogene addiction: setting the stage for molecularly targeted cancer therapy Genes & Dev., December 15, 2007; 21(24): 3214 - 3231. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Emlet, K. A. Brown, D. L. Kociban, A. A. Pollice, C. A. Smith, B. B. L. Ong, and S. E. Shackney Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines Mol. Cancer Ther., October 1, 2007; 6(10): 2664 - 2674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Wu, M. S. O'Reilly, R. R. Langley, R. Z. Tsan, C. H. Baker, N. Bekele, X. M. Tang, A. Onn, I. J. Fidler, and R. S. Herbst Expression of epidermal growth factor (EGF)/transforming growth factor-{alpha} by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice Mol. Cancer Ther., October 1, 2007; 6(10): 2652 - 2663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mandala, C. Moro, R. Labianca, and G. Ferretti Erlotinib in Pancreatic Cancer Patients: Do We Need More Information From the NCIC CTG Trial? J. Clin. Oncol., September 20, 2007; 25(27): 4320 - 4321. [Full Text] [PDF]
|
|
|
|
|
|
M. Ramanathan, G. Pinhal-Enfield, I. Hao, and S. J. Leibovich Synergistic Up-Regulation of Vascular Endothelial Growth Factor (VEGF) Expression in Macrophages by Adenosine A2A Receptor Agonists and Endotoxin Involves Transcriptional Regulation via the Hypoxia Response Element in the VEGF Promoter Mol. Biol. Cell, January 1, 2007; 18(1): 14 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Adjei Novel combinations based on epidermal growth factor receptor inhibition. Clin. Cancer Res., July 15, 2006; 12(14): 4446s - 4450s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Pore, Z. Jiang, A. Gupta, G. Cerniglia, G. D. Kao, and A. Maity EGFR Tyrosine Kinase Inhibitors Decrease VEGF Expression by Both Hypoxia-Inducible Factor (HIF)-1-Independent and HIF-1-Dependent Mechanisms. Cancer Res., March 15, 2006; 66(6): 3197 - 3204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Vitolo, L. Ciocci, G. Deriu, S. Spinelli, S. Cortese, L. Masuelli, S. Morrone, M. J. Filice, G. F. Coloni, P. G. Natali, et al. Laminin {alpha}2 Chain-Positive Vessels and Epidermal Growth Factor in Lung Neuroendocrine Carcinoma: A Model of a Novel Cooperative Role of Laminin-2 and Epidermal Growth Factor in Vessel Neoplastic Invasion and Metastasis Am. J. Pathol., March 1, 2006; 168(3): 991 - 1003. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Dresemann Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series Ann. Onc., October 1, 2005; 16(10): 1702 - 1708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Damiano, D. Melisi, C. Bianco, D. Raben, R. Caputo, G. Fontanini, R. Bianco, A. Ryan, A. R. Bianco, S. De Placido, et al. Cooperative Antitumor Effect of Multitargeted Kinase Inhibitor ZD6474 and Ionizing Radiation in Glioblastoma Clin. Cancer Res., August 1, 2005; 11(15): 5639 - 5644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bianco, T. Troiani, G. Tortora, and F. Ciardiello Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S159 - S171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sini, L. Wyder, C. Schnell, T. O'Reilly, A. Littlewood, R. Brandt, N. E. Hynes, and J. Wood The Antitumor and Antiangiogenic Activity of Vascular Endothelial Growth Factor Receptor Inhibition Is Potentiated by ErbB1 Blockade Clin. Cancer Res., June 15, 2005; 11(12): 4521 - 4532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Herbst, A. Onn, and A. Sandler Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications J. Clin. Oncol., May 10, 2005; 23(14): 3243 - 3256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Rege, C. Y. Fears, and C. L. Gladson Endogenous inhibitors of angiogenesis in malignant gliomas: Nature's antiangiogenic therapy Neuro-oncol, April 1, 2005; 7(2): 106 - 121. [Abstract] [PDF]
|
|
|
|
|
|
S. Kim, B. A. Schiff, O. G. Yigitbasi, D. Doan, S. A. Jasser, B. N. Bekele, M. Mandal, and J. N. Myers Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788 Mol. Cancer Ther., April 1, 2005; 4(4): 632 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Nigro, A. Misra, L. Zhang, I. Smirnov, H. Colman, C. Griffin, N. Ozburn, M. Chen, E. Pan, D. Koul, et al. Integrated Array-Comparative Genomic Hybridization and Expression Array Profiles Identify Clinically Relevant Molecular Subtypes of Glioblastoma Cancer Res., March 1, 2005; 65(5): 1678 - 1686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. W. Park, M. N. Younes, S. A. Jasser, O. G. Yigitbasi, G. Zhou, C. D. Bucana, B. N. Bekele, and J. N. Myers AEE788, a Dual Tyrosine Kinase Receptor Inhibitor, Induces Endothelial Cell Apoptosis in Human Cutaneous Squamous Cell Carcinoma Xenografts in Nude Mice Clin. Cancer Res., March 1, 2005; 11(5): 1963 - 1973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Tuccillo, M. Romano, T. Troiani, E. Martinelli, F. Morgillo, F. De Vita, R. Bianco, G. Fontanini, R. A. Bianco, G. Tortora, et al. Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor-2 and Epidermal Growth Factor Receptor Small Molecule Tyrosine Kinase Inhibitor, in Combination with SC-236, a Cyclooxygenase-2 Inhibitor Clin. Cancer Res., February 1, 2005; 11(3): 1268 - 1276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Camp, J. Summy, T. W. Bauer, W. Liu, G. E. Gallick, and L. M. Ellis Molecular Mechanisms of Resistance to Therapies Targeting the Epidermal Growth Factor Receptor Clin. Cancer Res., January 1, 2005; 11(1): 397 - 405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. P. Kenny, C. L. Keen, P. Jones, H.-J. Kung, H. H. Schmitz, and M. E. Gershwin Cocoa Procyanidins Inhibit Proliferation and Angiogenic Signals in Human Dermal Microvascular Endothelial Cells Following Stimulation by Low-Level H2O2 Experimental Biology and Medicine, September 1, 2004; 229(8): 765 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Chen, X. Zhang, M. Li, Z. Wang, H. S. Wieand, J. R. Grandis, and D. M. Shin Simultaneously Targeting Epidermal Growth Factor Receptor Tyrosine Kinase and Cyclooxygenase-2, an Efficient Approach to Inhibition of Squamous Cell Carcinoma of the Head and Neck Clin. Cancer Res., September 1, 2004; 10(17): 5930 - 5939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Blazquez, L. Gonzalez-Feria, L. Alvarez, A. Haro, M. L. Casanova, and M. Guzman Cannabinoids Inhibit the Vascular Endothelial Growth Factor Pathway in Gliomas Cancer Res., August 15, 2004; 64(16): 5617 - 5623. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Traxler, P. R. Allegrini, R. Brandt, J. Brueggen, R. Cozens, D. Fabbro, K. Grosios, H. A. Lane, P. McSheehy, J. Mestan, et al. AEE788: A Dual Family Epidermal Growth Factor Receptor/ErbB2 and Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor with Antitumor and Antiangiogenic Activity Cancer Res., July 15, 2004; 64(14): 4931 - 4941. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Q. Xiong, A. Rosenberg, A. LoBuglio, W. Schmidt, R. A. Wolff, J. Deutsch, M. Needle, and J. L. Abbruzzese Cetuximab, a Monoclonal Antibody Targeting the Epidermal Growth Factor Receptor, in Combination With Gemcitabine for Advanced Pancreatic Cancer: A Multicenter Phase II Trial J. Clin. Oncol., July 1, 2004; 22(13): 2610 - 2616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Murdaca, C. Treins, M.-N. Monthouel-Kartmann, R. Pontier-Bres, S. Kumar, E. Van Obberghen, and S. Giorgetti-Peraldi Grb10 Prevents Nedd4-mediated Vascular Endothelial Growth Factor Receptor-2 Degradation J. Biol. Chem., June 18, 2004; 279(25): 26754 - 26761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Parikh, F. Fan, W. B. Liu, S. A. Ahmad, O. Stoeltzing, N. Reinmuth, D. Bielenberg, C. D. Bucana, M. Klagsbrun, and L. M. Ellis Neuropilin-1 in Human Colon Cancer: Expression, Regulation, and Role in Induction of Angiogenesis Am. J. Pathol., June 1, 2004; 164(6): 2139 - 2151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wu, Q. Zhang, D. K. Ann, A. Akhondzadeh, H. S. Duong, D. V. Messadi, and A. D. Le Increased vascular endothelial growth factor may account for elevated level of plasminogen activator inhibitor-1 via activating ERK1/2 in keloid fibroblasts Am J Physiol Cell Physiol, April 1, 2004; 286(4): C905 - C912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Herbst, G. Giaccone, J. H. Schiller, R. B. Natale, V. Miller, C. Manegold, G. Scagliotti, R. Rosell, I. Oliff, J. A. Reeves, et al. Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial--INTACT 2 J. Clin. Oncol., March 1, 2004; 22(5): 785 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Y. Cheung Vascular Endothelial Growth Factor Activation of Intramembranous Absorption: A Critical Pathway for Amniotic Fluid Volume Regulation Reproductive Sciences, February 1, 2004; 11(2): 63 - 74. [Abstract] [PDF]
|
|
|
|
 |
|
 J. M. Mullin Epithelial Barriers, Compartmentation, and Cancer Sci. Signal., January 20, 2004; 2004(216): pe2 - pe2. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ciardiello, R. Bianco, R. Caputo, R. Caputo, V. Damiano, T. Troiani, D. Melisi, F. De Vita, S. De Placido, A. R. Bianco, et al. Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy Clin. Cancer Res., January 15, 2004; 10(2): 784 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. TORTORA and F. CIARDIELLO Antisense Targeting Protein Kinase A Type I as a Drug for Integrated Strategies of Cancer Therapy Ann. N.Y. Acad. Sci., December 1, 2003; 1002(1): 236 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. M. Boedefeld II, K. I. Bland, and M. J. Heslin Recent Insights Into Angiogenesis, Apoptosis, Invasion, and Metastasis in Colorectal Carcinoma Ann. Surg. Oncol., October 1, 2003; 10(8): 839 - 851. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Gardner and M. E. Olah Distinct Protein Kinase C Isoforms Mediate Regulation of Vascular Endothelial Growth Factor Expression by A2A Adenosine Receptor Activation and Phorbol Esters in Pheochromocytoma PC12 Cells J. Biol. Chem., April 18, 2003; 278(17): 15421 - 15428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ciardiello, R. Caputo, V. Damiano, R. Caputo, T. Troiani, D. Vitagliano, F. Carlomagno, B. M. Veneziani, G. Fontanini, A. R. Bianco, et al. Antitumor Effects of ZD6474, a Small Molecule Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, with Additional Activity against Epidermal Growth Factor Receptor Tyrosine Kinase Clin. Cancer Res., April 1, 2003; 9(4): 1546 - 1556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Benckert, S. Jonas, T. Cramer, Z. von Marschall, G. Schafer, M. Peters, K. Wagner, C. Radke, B. Wiedenmann, P. Neuhaus, et al. Transforming Growth Factor {beta}1 Stimulates Vascular Endothelial Growth Factor Gene Transcription in Human Cholangiocellular Carcinoma Cells Cancer Res., March 1, 2003; 63(5): 1083 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Pore, S. Liu, D. A. Haas-Kogan, D. M. O'Rourke, and A. Maity PTEN Mutation and Epidermal Growth Factor Receptor Activation Regulate Vascular Endothelial Growth Factor (VEGF) mRNA Expression in Human Glioblastoma Cells by Transactivating the Proximal VEGF Promoter Cancer Res., January 1, 2003; 63(1): 236 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Shimizu, J.-Y. Jiang, H. Sasada, and E. Sato Changes of Messenger RNA Expression of Angiogenic Factors and Related Receptors During Follicular Development in Gilts Biol Reprod, December 1, 2002; 67(6): 1846 - 1852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Li, C. Ye, C. Feng, F. Riedel, X. Liu, Q. Zeng, and J. R. Grandis Enhanced Antiangiogenic Therapy of Squamous Cell Carcinoma by Combined Endostatin and Epidermal Growth Factor Receptor-Antisense Therapy Clin. Cancer Res., November 1, 2002; 8(11): 3570 - 3578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Yen, N. Benlimame, Z.-R. Nie, D. Xiao, T. Wang, A.-E. A. Moustafa, H. Esumi, J. Milanini, N. E. Hynes, G. Pages, et al. Differential Regulation of Tumor Angiogenesis by Distinct ErbB Homo- and Heterodimers Mol. Biol. Cell, November 1, 2002; 13(11): 4029 - 4044. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. H. Baker, D. Kedar, M. F. McCarty, R. Tsan, K. L. Weber, C. D. Bucana, and I. J. Fidler Blockade of Epidermal Growth Factor Receptor Signaling on Tumor Cells and Tumor-Associated Endothelial Cells for Therapy of Human Carcinomas Am. J. Pathol., September 1, 2002; 161(3): 929 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-M. Huang, J. Li, E. A. Armstrong, and P. M. Harari Modulation of Radiation Response and Tumor-induced Angiogenesis after Epidermal Growth Factor Receptor Inhibition by ZD1839 (Iressa) Cancer Res., August 1, 2002; 62(15): 4300 - 4306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Treins, S. Giorgetti-Peraldi, J. Murdaca, G. L. Semenza, and E. Van Obberghen Insulin Stimulates Hypoxia-inducible Factor 1 through a Phosphatidylinositol 3-Kinase/Target of Rapamycin-dependent Signaling Pathway J. Biol. Chem., July 26, 2002; 277(31): 27975 - 27981. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. TORTORA and F. CIARDIELLO Protein Kinase A as Target for Novel Integrated Strategies of Cancer Therapy Ann. N.Y. Acad. Sci., June 1, 2002; 968(1): 139 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-M. Huang, J. Li, and P. M. Harari Molecular Inhibition of Angiogenesis and Metastatic Potential in Human Squamous Cell Carcinomas after Epidermal Growth Factor Receptor Blockade Mol. Cancer Ther., May 1, 2002; 1(7): 507 - 514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. H. Baker, C. C. Solorzano, and I. J. Fidler Blockade of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling for Therapy of Metastatic Human Pancreatic Cancer Cancer Res., April 1, 2002; 62(7): 1996 - 2003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. TAYLOR, D. I. LEBOVIC, and M. D. MUELLER Angiogenic Factors in Endometriosis Ann. N.Y. Acad. Sci., March 1, 2002; 955(1): 89 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Maeno, T. Tanaka, Y. Sando, T. Suga, Y. Maeno, J. Nakagawa, T. Hosono, M. Sato, H. Akiyama, S. Kishi, et al. Stimulation of Vascular Endothelial Growth Factor Gene Transcription by all trans Retinoic Acid through Sp1 and Sp3 Sites in Human Bronchioloalveolar Carcinoma Cells Am. J. Respir. Cell Mol. Biol., February 1, 2002; 26(2): 246 - 253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Tortora, R. Caputo, V. Damiano, G. Fontanini, D. Melisi, B. Maria Veneziani, F. Zunino, A. R. Bianco, and F. Ciardiello Oral Administration of a Novel Taxane, an Antisense Oligonucleotide Targeting Protein Kinase A, and the Epidermal Growth Factor Receptor Inhibitor Iressa Causes Cooperative Antitumor and Antiangiogenic Activity Clin. Cancer Res., December 1, 2001; 7(12): 4156 - 4163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Treins, S. Giorgetti-Peraldi, J. Murdaca, and E. Van Obberghen Regulation of Vascular Endothelial Growth Factor Expression by Advanced Glycation End Products J. Biol. Chem., November 16, 2001; 276(47): 43836 - 43841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Solorzano, C. H. Baker, R. Tsan, P. Traxler, P. Cohen, E. Buchdunger, J. J. Killion, and I. J. Fidler Optimization for the Blockade of Epidermal Growth Factor Receptor Signaling for Therapy of Human Pancreatic Carcinoma Clin. Cancer Res., August 1, 2001; 7(8): 2563 - 2572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Maher, F. B. Furnari, R. M. Bachoo, D. H. Rowitch, D. N. Louis, W. K. Cavenee, and R. A. DePinho Malignant glioma: genetics and biology of a grave matter Genes & Dev., June 1, 2001; 15(11): 1311 - 1333. [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Hovey, A. S. Goldhar, J. Baffi, and B. K. Vonderhaar Transcriptional Regulation of Vascular Endothelial Growth Factor Expression in Epithelial and Stromal Cells during Mouse Mammary Gland Development Mol. Endocrinol., May 1, 2001; 15(5): 819 - 831. [Abstract] [Full Text]
|
|
|
|
|
|
F. Ciardiello, R. Caputo, R. Bianco, V. Damiano, G. Fontanini, S. Cuccato, S. De Placido, A. R. Bianco, and G. Tortora Inhibition of Growth Factor Production and Angiogenesis in Human Cancer Cells by ZD1839 (Iressa), a Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Clin. Cancer Res., May 1, 2001; 7(5): 1459 - 1465. [Abstract] [Full Text]
|
|
|
|
|
|
H. Ding, L. Roncari, X. Wu, N. Lau, P. Shannon, A. Nagy, and A. Guha Expression and hypoxic regulation of angiopoietins in human astrocytomas Neuro-oncol, January 1, 2001; 3(1): 1 - 10. [Abstract] [PDF]
|
|
|
|
 |
|
 A. E. G. Lenferink, J. F. Simpson, L. K. Shawver, R. J. Coffey, J. T. Forbes, and C. L. Arteaga Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice PNAS, August 6, 2000; (2000) 160564197. [Abstract] [Full Text]
|
|
|
|
|
|
C. J. Bruns, C. C. Solorzano, M. T. Harbison, S. Ozawa, R. Tsan, D. Fan, J. Abbruzzese, P. Traxler, E. Buchdunger, R. Radinsky, et al. Blockade of the Epidermal Growth Factor Receptor Signaling by a Novel Tyrosine Kinase Inhibitor Leads to Apoptosis of Endothelial Cells and Therapy of Human Pancreatic Carcinoma Cancer Res., June 1, 2000; 60(11): 2926 - 2935. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Bruns, M. T. Harbison, D. W. Davis, C. A. Portera, R. Tsan, D. J. McConkey, D. B. Evans, J. L. Abbruzzese, D. J. Hicklin, and R. Radinsky Epidermal Growth Factor Receptor Blockade with C225 Plus Gemcitabine Results in Regression of Human Pancreatic Carcinoma Growing Orthotopically in Nude Mice by Antiangiogenic Mechanisms Clin. Cancer Res., May 1, 2000; 6(5): 1936 - 1948. [Abstract] [Full Text]
|
|
|
|
